Clinical Trials

Verified stories whose regulatory record supports clinical-trial access. Eligibility and enrollment are never guaranteed.

Filter clinical trials

Results

97 verified trial-access stories match your filters.

Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.

Trial Watch: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Breast Cancer
Trial identifier
NCT05827081
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants ages 18 Years to 100 Years with Early Breast Cancer who meet the study-specific registry eligibility criteria.
Last reviewed
2026-08-18

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-18

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Breast Cancer
Trial identifier
NCT07544056
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants ages 18 Years to 75 Years with Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed
2026-08-18

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-18

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Lung Cancer
Trial identifier
NCT07431827
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Non-small Cell Lung Cancer who meet the study-specific registry eligibility criteria.
Last reviewed
2026-08-17

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-17

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Leukemia
Trial identifier
NCT07223021
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 1 Year and older with B-cell Acute Lymphoblastic Leukemia who meet the study-specific registry eligibility criteria.
Last reviewed
2026-08-17

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-17

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Stomach (Gastric) Cancer
Trial identifier
NCT07392892
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma who meet the study-specific registry eligibility criteria.
Last reviewed
2026-08-17

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-17

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Lung Cancer
Trial identifier
NCT07365241
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Small Cell Lung Cancer who meet the study-specific registry eligibility criteria.
Last reviewed
2026-08-14

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-14

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Lymphoma
Trial identifier
NCT07634471
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Follicular Lymphoma who meet the study-specific registry eligibility criteria.
Last reviewed
2026-08-14

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-14

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Kidney (Renal) Cancer
Trial identifier
NCT04736706
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Carcinoma, Renal Cell who meet the study-specific registry eligibility criteria.
Last reviewed
2026-08-14

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-14

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Lung Cancer
Trial identifier
NCT06875310
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Carcinoma, Non-Small-Cell Lung who meet the study-specific registry eligibility criteria.
Last reviewed
2026-08-14

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-14

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Breast Cancer
Trial identifier
NCT07391774
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma who meet the study-specific registry eligibility criteria.
Last reviewed
2026-08-14

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-14

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.